The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock List

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Sun., Nov. 29, 9:35 PM

Slide #19. Alcobra Ltd. Secondary Offering

Company: Alcobra Ltd. (ADHD)
Date announced: 11/11/2015
Shares Offered: 6,175,000
Date of Pricing: 11/13/2015
Price Per Share: $6.50
Secondary Offering Details: Alcobra Ltd. (Nasdaq:ADHD) announced today that it intends to offer its ordinary shares in an underwritten public offering. Jefferies LLC and Barclays Capital Inc. are acting as joint book-running managers for the offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Alcobra also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the ordinary shares offered to the public. -updated 11/13- Alcobra Ltd. (Nasdaq:ADHD) announced the pricing of its previously announced underwritten public offering of 6,175,000 ordinary shares at an offering price of $6.50 per share. Gross proceeds from the sale of the shares by Alcobra before underwriting discounts and commissions and other offering expenses are expected to be approximately $40.1 million. In connection with the offering, Alcobra has also granted the underwriters a 30-day option to purchase up to an additional 926,250 ordinary shares. The offering is expected to close on or about November 18, 2015, subject to customary closing conditions. Alcobra plans to use the net proceeds from the offering to fund its future clinical development program and for general corporate purposes.

Alcobra is an emerging biopharmaceutical company primarily focused on the development and commercialization of a proprietary oral drug candidate, MDX, to treat ADHD and other cognitive dysfunctions including Fragile X Syndrome. The most common available treatments for ADHD are stimulants that increase the brain chemicals dopamine and norepinephrine. Stimulants have significant side effects, and are classified as controlled substances which have significant potential for misuse, abuse and addiction. MDX is not a stimulant, and works with a different mechanism of action. MDX is a proprietary, combined rapid onset/extended release formulation of the chemical Pyridoxine Pyroglutamate.
Open the ADHD Page at The Online Investor »

Company Name:  Alcobra Ltd.
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding ADHD:  1
Total Market Value Held by ETFs:  $99469
Total Market Capitalization:  $90.00M
% of Market Cap. Held by ETFs:  0.11%

Open the ADHD Page at The Online Investor (in a new window) »

November 29, 2015    9:35 PM Eastern
Quotes delayed 20 minutes

Strong Buy (4.00 out of 4)
98th percentile
(ranked higher than approx. 98% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | | Copyright © 1998 - 2015, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.